Stayble Therapeutics AB (publ) reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported revenue was SEK 0.204 million. Net loss was SEK 6.49 million compared to SEK 2.46 million a year ago. Basic loss per share from continuing operations was SEK 0.47 compared to SEK 0.18 a year ago.
For the six months, revenue was SEK 0.222 million. Net loss was SEK 14.08 million compared to SEK 4.52 million a year ago. Basic loss per share from continuing operations was SEK 1.02 compared to SEK 0.33 a year ago.